Study details
Enrolling now
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
NCT IDNCT05657873ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
68
Study length
about 3 years
Ages
18+
Locations
9 sites in FL, NJ, NY +1
What this study is about
This trial is testing whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Anti-PD-(L)1 based immunotherapy
- 2.Receive L-SABR
- 3.Take Platinum based chemotherapy
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized (Open Label)
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
immunotherapy
Endpoints
Primary: Median progression-free survival
Body systems
Oncology